Background The Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) has launched several large-scale trials to determine the best strategies for gaining and sustaining control of schistosomiasis and transitioning toward elimination. In C？te d’Ivoire, a 5-year cluster-randomized trial is being implemented in 75 schools to sustain the control of schistosomiasis mansoni. We report Schistosoma mansoni infection levels in children one year after the initial school-based treatment (SBT) with praziquantel and compare with baseline results to determine the effect of the intervention. Methodology The baseline cross-sectional survey was conducted in late 2011/early 2012 and the first follow-up in May 2013. Three consecutive stool samples were collected from 9- to 12-year-old children in 75 schools at baseline and 50 schools at follow-up. Stool samples were subjected to duplicate Kato-Katz thick smears. Directly observed treatment (DOT) coverage of the SBT was assessed and the prevalence and intensity of S. mansoni infection compared between baseline and follow-up. Principal Findings The S. mansoni prevalence in the 75 schools surveyed at baseline was 22.1% (95% confidence interval (CI): 19.5–24.4%). The DOT coverage was 84.2%. In the 50 schools surveyed at baseline and one year after treatment, the overall prevalence of S. mansoni infection decreased significantly from 19.7% (95% CI: 18.5–20.8%) to 12.8% (95% CI: 11.9–13.8%), while the arithmetic mean S. mansoni eggs per gram of stool (EPG) among infected children slightly increased from 92.2 EPG (95% CI: 79.2–105.3 EPG) to 109.3 EPG (95% CI: 82.7–135.9 EPG). In two of the 50 schools, the prevalence increased significantly, despite a DOT coverage of >75%. Conclusions/Significance One year after the initial SBT, the S. mansoni prevalence had decreased. Despite this positive trend, an increase was observed in some schools. Moreover, the infection intensity among S. mansoni-infected children was slightly higher at the 1-year follow-up compared to the baseline situation. Our results emphasize the heterogeneity of transmission dynamics and provide a benchmark for the future yearly follow-up surveys of this multi-year SCORE intervention study.
References
[1]
WHO (2014) Schistosomiasis: number of people receiving preventive chemotherapy in 2012. Wkly Epidemiol Rec 89: 21–28. pmid:24446558
[2]
WHO (2015) Schistosomiasis: number of people treated worldwide in 2013. Wkly Epidemiol Rec 90: 25–32. pmid:25638822
[3]
WHO (1985) The control of schistosomiasis: report of a WHO expert committee. WHO Tech Rep Ser 728: 1–114. doi: 10.1017/s0031182000081403
[4]
Bergquist NR (2002) Schistosomiasis: from risk assessment to control. Trends Parasitol 18: 309–314. pmid:12379951 doi: 10.1016/s1471-4922(02)02301-2
[5]
Doenhoff MJ, Kusel JR, Coles GC, Cioli D (2002) Resistance of Schistosoma mansoni to praziquantel: is there a problem? Trans R Soc Trop Med Hyg 96: 465–469. pmid:12474468 doi: 10.1016/s0035-9203(02)90405-0
[6]
Singer BH, de Castro MC (2007) Bridges to sustainable tropical health. Proc Natl Acad Sci USA 104: 16038–16043. pmid:17913894 doi: 10.1073/pnas.0700900104
[7]
Zhang Y, MacArthur C, Mubila L, Baker S (2010) Control of neglected tropical diseases needs a long-term commitment. BMC Med 8: 67. doi: 10.1186/1741-7015-8-67. pmid:21034473
[8]
Thétiot-Laurent SA-L, Boissier J, Robert A, Meunier B (2013) Schistosomiasis chemotherapy. Angew Chem 52: 7936–7956. doi: 10.1002/anie.201208390
[9]
WHO (2006) The global programme for eliminating lymphatic filariasis. Wkly Epidemiol Rec 81: 221–232. pmid:16749186
[10]
WHO (2013) Schistosomiasis: progress report 2001–2011, strategic plan 2012–2020. Geneva: World Health Organization.
[11]
WHO (2012) Schistosomiasis: population requiring preventive chemotherapy and number of people treated in 2010. Wkly Epidemiol Rec 87: 37–44. pmid:22308580
[12]
WHO (2006) Preventive chemotherapy in human helminthiasis: coordinated use of anthelminthic drugs in control interventions. Geneva: World Health Organization.
[13]
Colley DG (2014) Morbidity control of schistosomiasis by mass drug administration: how can we do it best and what will it take to move on to elimination? Trop Med Health 42: 25–32. doi: 10.2149/tmh.2014-s04
[14]
Samuels AM, Matey E, Mwinzi PNM, Wiegand RE, Muchiri G, Ireri E, et al. (2012) Schistosoma mansoni morbidity among school-aged children: a SCORE project in Kenya. Am J Trop Med Hyg 87: 874–882. doi: 10.4269/ajtmh.2012.12-0397. pmid:22987651
[15]
Assaré RK, Knopp S, N’Guessan NA, Yapi A, Tian-Bi YNT, Yao PK, et al. (2014) Sustaining control of schistosomiasis mansoni in moderate endemicity areas in western C？te d’Ivoire: a SCORE study protocol. BMC Public Health 14: 1290. doi: 10.1186/1471-2458-14-1290. pmid:25519880
[16]
WHO (2002) Prevention and control of schistosomiasis and soil-transmitted helminthiasis: report of a WHO expert committee. WHO Tech Rep Ser 912: 1–57.
[17]
Assaré RK, Hürlimann E, Ouattara M, N’Guessan N, Tian-Bi Y-N, Yapi A, et al. (2015) Sustaining the control of Schistosoma mansoni in western C？te d'Ivoire: baseline findings before the implementation of a randomized trial. Am J Trop Med Hyg (in press; doi: 10.4269/ajtmh.15-0530).
[18]
Kouamé KF, Bernier M, Goné DL, Saley MB, Lefèbvre R, Soro N, et al. (2007) Intégration de données géospatiales dans un modèle hydrologique distribué pour la simulation des écoulements des eaux en milieu tropical humide de C？te d’Ivoire (Afrique de l’Ouest). Revue Télédétection 7: 217–235.
[19]
Aregheore EM. Country pasture/forage resource profile; 2009: pp 30.
[20]
Kouamé MK, Ouattara A, Dietoa MY, Gourène G (2006) Alimentation du Clupeidae Pellonula leonensis dans le lac de barrage de Buyo (C？te d’Ivoire). Cybium 30: 145–150.
[21]
Fürst T, Raso G, Acka CA, Tschannen AB, N’Goran EK, Utzinger J (2009) Dynamics of socioeconomic risk factors for neglected tropical diseases and malaria in an armed conflict. PLoS Negl Trop Dis 3: e513. doi: 10.1371/journal.pntd.0000513. pmid:19907632
[22]
Acka CA, Raso G, N’Goran EK, Tschannen AB, Bogoch II, Seraphin E, et al. (2010) Parasitic worms: knowledge, attitudes, and practices in western C？te d’Ivoire with implications for integrated control. PLoS Negl Trop Dis 4: e910. doi: 10.1371/journal.pntd.0000910. pmid:21200423
[23]
Matthys B, Tschannen AB, Tian-Bi NT, Comoé H, Diabaté S, Traoré M, et al. (2007) Risk factors for Schistosoma mansoni and hookworm in urban farming communities in western C？te d’Ivoire. Trop Med Int Health 12: 709–723. pmid:17550468 doi: 10.1111/j.1365-3156.2007.01841.x
[24]
Luginbühl A (2008) Sustainable prevention of water associated infection risks: an awareness campaign using visual media. In: Hirsch Hadorn G, Hoffmann-Riem H, Biber-Klemm S, Grossenbacher-Mansuy W, Joye D, Pohl C, et al. (eds), Handbook of transdisciplinary research, pp. 293–304.
Katz N, Chaves A, Pellegrino J (1972) A simple device for quantitative stool thick-smear technique in schistosomiasis mansoni. Rev Inst Med Trop S？o Paulo 14: 397–400. pmid:4675644
[27]
Speich B, Ali SM, Ame SM, Albonico M, Utzinger J, Keiser J (2015) Quality control in the diagnosis of Trichuris trichiura and Ascaris lumbricoides using the Kato-Katz technique: experience from three randomised controlled trials. Parasit Vectors 8: 82. doi: 10.1186/s13071-015-0702-z. pmid:25652120
[28]
Montresor A, Crompton DWT, Bundy DAP, Hall A, Savioli L (1998) Guidelines for the evaluation of soil-transmitted helminthiasis and schistosomiasis at community level. Geneva: World Health Organization.
[29]
Webster JP, Molyneux DH, Hotez PJ, Fenwick A (2014) The contribution of mass drug administration to global health: past, present and future. Philos Trans R Soc Lond B Biol Sci 369: 20130434. doi: 10.1098/rstb.2013.0434. pmid:24821920
[30]
Zhang Y, Koukounari A, Kabatereine N, Fleming F, Kazibwe F, Tukahebwa E, et al. (2007) Parasitological impact of 2-year preventive chemotherapy on schistosomiasis and soil-transmitted helminthiasis in Uganda. BMC Med 5: 27. pmid:17767713 doi: 10.1186/1741-7015-5-27
[31]
Ahmed AM, El Tash LA, Mohamed EY, Adam I (2012) High levels of Schistosoma mansoni infections among schoolchildren in central Sudan one year after treatment with praziquantel. J Helminthol 86: 228–232. doi: 10.1017/S0022149X11000290. pmid:21729382
[32]
Kabatereine NB, Tukahebwa E, Kazibwe F, Namwangye H, Zaramba S, Brooker S, et al. (2006) Progress towards countrywide control of schistosomiasis and soil-transmitted helminthiasis in Uganda. Trans R Soc Trop Med Hyg 100: 208–215. pmid:16378628 doi: 10.1016/j.trstmh.2005.03.015
[33]
Hodges MH, Dada N, Warmsley A, Paye J, Bangura MM, Nyorkor E, et al (2012) Mass drug administration significantly reduces infection of Schistosoma mansoni and hookworm in school children in the national control program in Sierra Leone. BMC Infect Dis 12: 16. doi: 10.1186/1471-2334-12-16. pmid:22264258
[34]
Sesay S, Paye J, Bah MS, McCarthy FM, Conteh A, Sonnie M, et al. (2014) Schistosoma mansoni infection after three years of mass drug administration in Sierra Leone. Parasit Vectors 7: 14. doi: 10.1186/1756-3305-7-14. pmid:24401567
[35]
Sukwa TY, Boatin BA, Wurapa FK (1998) A three year follow-up of chemotherapy with praziquantel in a rural Zambian community endemic for schistosomiasis mansoni. Trans R Soc Trop Med Hyg 82: 258–260. doi: 10.1016/0035-9203(88)90439-7
[36]
Masaku J, Madigu N, Okoyo C, Njenga SM (2015) Current status of Schistosoma mansoni and the factors associated with infection two years following mass drug administration programme among primary school children in Mwea irrigation scheme: a cross-sectional study. BMC Public Health 15: 739. doi: 10.1186/s12889-015-1991-z. pmid:26231050
[37]
Zein ZA (1989) Spontaneous reduction in Schistosoma mansoni infection in endemic communities of the lake Tana basin, north-western Ethiopia. Trans R Soc Trop Med Hyg 83: 656–658. pmid:2515631 doi: 10.1016/0035-9203(89)90389-1
[38]
Ndyomugyenyi R, Minjas JN (2001) Urinary schistosomiasis in schoolchildren in Dar-es-Salaam, Tanzania, and the factors influencing its transmission. Ann Trop Med Parasitol 95: 697–706. pmid:11784423 doi: 10.1080/00034980120097151
[39]
Gazzinelli A, Hightower A, LoVerde PT, Haddad JP, Pereira WR, Bethony J, et al. (2006) The spatial distribution of Schistosoma mansoni infection before and after chemotherapy in the Jequitinhonha Valley in Brazil. Mem Inst Oswaldo Cruz 101: 63–71. pmid:17308749 doi: 10.1590/s0074-02762006000900010
[40]
Stothard JR, French MD, Khamis IS, Basá？ez MG, Rollinson D (2009) The epidemiology and control of urinary schistosomiasis and soil-transmitted helminthiasis in schoolchildren on Unguja Island, Zanzibar. Trans R Soc Trop Med Hyg 103: 1031–1044. doi: 10.1016/j.trstmh.2009.03.024. pmid:19409588
[41]
N’Goran EK, Utzinger J, N’Guessan AN, Müller I, Zamblé K, Lohourignon KL, et al. (2001) Reinfection with Schistosoma haematobium following school-based chemotherapy with praziquantel in four highly endemic villages in C？te d’Ivoire. Trop Med Int Health 6: 817–825. pmid:11679130 doi: 10.1046/j.1365-3156.2001.00785.x
[42]
Garba A, Lamine MS, Barkire N, Djibo A, Sofo B, Gouvras AN, et al. (2003) Efficacy and safety of two closely spaced doses of praziquantel against Schistosoma haematobium and S. mansoni and re-infection patterns in school-aged children in Niger. Acta Trop 128: 334–344. doi: 10.1016/j.actatropica.2012.08.008
[43]
Bonfoh B, Raso G, Koné I, Dao D, Girardin O, Cissé G, et al. (2011) Research in a war zone. Nature 474: 569–571. doi: 10.1038/474569a. pmid:21720345
[44]
Ernould JC, Ba K, Sellin B (1999) Increase of intestinal schistosomiasis after praziquantel treatment in a Schistosoma haematobium and Schistosoma mansoni mixed focus. Acta Trop 73: 143–152. pmid:10465054 doi: 10.1016/s0001-706x(99)00013-3
[45]
Landouré A, Dembélé R, Goita S, Kane M, Tuinsma M, Sacko M, et al. (2012) Significantly reduced intensity of infection but persistent prevalence of schistosomiasis in a highly endemic region in Mali after repeated treatment. PLoS Negl Trop Dis 6: e1774. doi: 10.1371/journal.pntd.0001774. pmid:22860153
[46]
Kabatereine NB, Vennervald JB, Ouma JH, Kemijumbi J, Butterworth AE, Dunne DW, et al. (1999) Adult resistance to schistosomiasis mansoni: age-dependence of reinfection remains constant in communities with diverse exposure patterns. Parasitology 118: 101–105. pmid:10070667 doi: 10.1017/s0031182098003576
[47]
Stothard JR, Chitsulo L, Kristensen TK, Utzinger J (2009) Control of schistosomiasis in sub-Saharan Africa: progress made, new opportunities and remaining challenges. Parasitology 136: 1665–1675. doi: 10.1017/S0031182009991272. pmid:19814845
[48]
Wang W, Wang L, Liang YS (2012) Susceptibility or resistance of praziquantel in human schistosomiasis: a review. Parasitol Res 111: 1871–1877. doi: 10.1007/s00436-012-3151-z. pmid:23052781
Wang LD, Chen HG, Guo JG, Zeng XJ, Hong XL, Xiong JJ, et al. (2009) A strategy to control transmission of Schistosoma japonicum in China. N Engl J Med 360: 121–128. doi: 10.1056/NEJMoa0800135. pmid:19129526
[51]
Lo NC, Bogoch II, Blackburn BG, Raso G, N'Goran EK, Coulibaly JT, et al. (2015) Comparison of community-wide, integrated mass drug administration strategies for schistosomiasis and soil-transmitted helminthiasis: a cost-effectiveness modelling study. Lancet Glob Health 3: e629–638. doi: 10.1016/S2214-109X(15)00047-9. pmid:26385302
[52]
Utzinger J, Raso G, Brooker S, de Savigny D, Tanner M, ？rnbjerg N, et al. (2009) Schistosomiasis and neglected tropical diseases: towards integrated and sustainable control and a word of caution. Parasitology 136: 1859–1874. doi: 10.1017/S0031182009991600. pmid:19906318
